Cargando…
Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645991/ http://dx.doi.org/10.1186/2051-1426-3-S2-P146 |
| _version_ | 1782400908049514496 |
|---|---|
| author | Chen, Robert Armand, Phillippe Fanale, Michelle A Ribrag, Vincent Zinzani, Pier Luigi Ricart, Alejandro D Thompson, Seth Balakumaran, Arun Molin, Daniel Shipp, Margaret A Moskowitz, Craig H |
| author_facet | Chen, Robert Armand, Phillippe Fanale, Michelle A Ribrag, Vincent Zinzani, Pier Luigi Ricart, Alejandro D Thompson, Seth Balakumaran, Arun Molin, Daniel Shipp, Margaret A Moskowitz, Craig H |
| author_sort | Chen, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645991 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46459912015-11-20 Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 Chen, Robert Armand, Phillippe Fanale, Michelle A Ribrag, Vincent Zinzani, Pier Luigi Ricart, Alejandro D Thompson, Seth Balakumaran, Arun Molin, Daniel Shipp, Margaret A Moskowitz, Craig H J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645991/ http://dx.doi.org/10.1186/2051-1426-3-S2-P146 Text en Copyright © 2015 Chen et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Chen, Robert Armand, Phillippe Fanale, Michelle A Ribrag, Vincent Zinzani, Pier Luigi Ricart, Alejandro D Thompson, Seth Balakumaran, Arun Molin, Daniel Shipp, Margaret A Moskowitz, Craig H Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title_full | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title_fullStr | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title_full_unstemmed | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title_short | Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 |
| title_sort | phase ii study of pembrolizumab (mk-3475) for relapsed/refractory classical hodgkin lymphoma (r/r chl): keynote-087 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645991/ http://dx.doi.org/10.1186/2051-1426-3-S2-P146 |
| work_keys_str_mv | AT chenrobert phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT armandphillippe phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT fanalemichellea phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT ribragvincent phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT zinzanipierluigi phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT ricartalejandrod phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT thompsonseth phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT balakumaranarun phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT molindaniel phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT shippmargareta phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 AT moskowitzcraigh phaseiistudyofpembrolizumabmk3475forrelapsedrefractoryclassicalhodgkinlymphomarrchlkeynote087 |